Topical doxorubicin hydrochloride therapy for carcinoma in situ of the bladder: a followup.
A total of 10 patients with histologically proved carcinoma in situ of the bladder had remission of tumor after topical chemotherapy with doxorubicin hydrochloride for 24 months. Of the 10 patients 3 suffered new areas of carcinoma in situ 9 to 12 months after termination of intravesical chemotherapy. Furthermore, 1 of these 3 patients had a distal ureteral tumor. Fibrosis of the submucosal tissue was observed in every patient but a decrease in bladder capacity was observed in only 1 with prior radiotherapy.
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000473:pathology; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology
D004317:Doxorubicin